Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

In recent times, the market size for anti-vascular endothelial growth factor therapeutics has seen a slight decrease. However, projections indicate an increase from $12.2 billion in 2024 to $12.17 billion in 2025, which corresponds to a compound annual growth rate (CAGR) of -0.2%. The expansion during the historic period can be linked to an escalation in age-related macular degeneration, a higher rate of diabetic retinopathy, advancements in the diagnosis of retinal diseases, clinical achievements and efficiency, as well as a transition to outpatient treatment.

The market size for anti-vascular endothelial growth factor therapeutics is predicted to experience slight expansion in the coming years, reaching $13.17 billion in 2029 with a compound annual growth rate (CAGR) of 2.0%. This projected growth during the forecast period can be linked to factors such as the aging population and prevalence of ocular illnesses, broader usage in retinal disorder treatments, introduction of future-generation therapies, sharpened focus on preemptive measures, and increased accessibility to treatment through global health initiatives. Key trends expected during the forecast period include its heightened use in cancer treatments, preference towards combined therapy procedures in ophthalmology, investigation into biosimilar versions, study into resistance mechanisms, and incorporation with imaging technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp

What Forces Are Driving The Growth Of The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The escalating number of cases of ophthalmic diseases is anticipated to spur the expansion of the anti-vascular endothelial growth factor therapeutics market. The term “prevalence of ophthalmic diseases” denotes the count or percentage of individuals in a certain population who have been identified with or exhibit distinct eye-related diseases or conditions. Anti-vascular endothelial growth factor (VEGF) therapeutics are effectively reducing the incident rate of such diseases by treating issues like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, the World Health Organization, a Swiss-based global public health body, reported in October 2022 that approximately 2.2 billion people worldwide have problems with near or distant vision, and 1 billion people struggle with vision impairment. Furthermore, of these, 88.4 million are suffering from refractive errors, 94 million are dealing with cataracts, 8 million have age-related macular degeneration, and around 3.9 million are affected by diabetic retinopathy. Consequently, the rising number of ophthalmic disease cases is propelling the growth of the anti-vascular endothelial growth factor therapeutics market.

What Is The Overview Of Market Segmentation In The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:

1) By Eylea: Indications, Dosage Forms

2) By Lucentis: Indications, Dosage Forms

3) By Beovu: Indications, Dosage Forms

What Future Market Trends Are Projected For The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

Progress in therapeutic treatments is an emerging trend being observed in the anti-vascular endothelial growth factor therapeutics market. To maintain their market prominence, entities in this market are embracing advanced therapeutic strategies. As an illustration, in May 2022, Ashvattha Therapeutics Inc., a clinical-stage biopharmaceutical firm based in the US, revealed phase 1 safety data for healthy subjects for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates using the D-4517.2 therapy. This first-in-class therapy is designed to address the unresolved needs of DME illnesses. D-4517.2 therapy is formulated for individual use via an autoinjector. This autoinjector D-4517.2 allows patients to dispense the medicine once a month in the privacy of their home.

Who Are The Primary Players Operating Across The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Which Region Offers The Most Growth Potential For The Anti-Vascular Endothelial Growth Factor Therapeutics Market Through 2029?

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model